Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). Academic Article uri icon

Overview

abstract

  • A structure-activity relationship study was carried out on a series of thiohydantoins and their analogues 14 which led to the discovery of 92 (MDV3100) as the clinical candidate for the treatment of hormone refractory prostate cancer.

publication date

  • April 8, 2010

Research

keywords

  • Androgen Receptor Antagonists
  • Orchiectomy
  • Prostatic Neoplasms
  • Thiohydantoins

Identity

PubMed Central ID

  • PMC3180999

Scopus Document Identifier

  • 77950574393

Digital Object Identifier (DOI)

  • 10.1021/jm901488g

PubMed ID

  • 20218717

Additional Document Info

volume

  • 53

issue

  • 7